Previous 10 | Next 10 |
Clearside Biomedical (NASDAQ: CLSD ): Q1 GAAP EPS of -$0.07 beats by $0.05 . More news on: Clearside Biomedical, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
ALPHARETTA, Ga., May 08, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, today reported financial results ...
Teva Receives Positive Ruling on Cancer Drug Patents Teva Pharmaceuticals Industries Ltd. ( TEVA ) received a boost as it received positive ruling on its Bendeka cancer drug. The ruling may ensure that the drug is not thwarted by generic competition in the market for a considerable period...
Clearside Biomedical ( CLSD -9.2% ) slips on below-average volume in reaction to a delay in its planned resubmission of a U.S. marketing application for Xipere (triamcinolone acetonide suprachoroidal injectable suspension) until Q4 (the original expectation was Q1). More news on: Clear...
NeuBase Therapeutics (NASDAQ: NBSE ) -15% on equity offering . More news on: NeuBase Therapeutics, Inc., Yield10 Bioscience, Inc., Blueprint Medicines Corporation, Stocks on the move, , Read more ...
- Management to Host Webcast and Conference Call Today at 8:30 A.M. ET - ALPHARETTA, Ga., April 28, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for...
ALPHARETTA, Ga., April 22, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that Nancy J. H...
ALPHARETTA, Ga., April 09, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today the formation o...
ALPHARETTA, Ga., April 08, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that George Las...
These Penny Stocks Are Reporting Key Data This Week Looking for penny stocks to buy can be a task especially if there are many to choose from. When it comes to weekend research one of the main search topics involves potential catalysts. So you might say, “It’s the weekend, no o...
News, Short Squeeze, Breakout and More Instantly...
Clearside Biomedical Inc. Company Name:
CLSD Stock Symbol:
NASDAQ Market:
Clearside Biomedical Inc. Website:
ALPHARETTA, Ga., July 22, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), has opened registration for its virtual key opinion l...
ALPHARETTA, Ga., July 11, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today the appointment of Glenn C. Yiu, M.D....
- Webinar to be held on Wednesday, July 24, 2024 at 8:00 am ET - - Retina Specialists to Provide Insights and Real-World Experience with Suprachoroidal Drug Delivery - - Target Profile for CLS-AX in Wet AMD Landscape and Potential Opportunities for Clearside Pipeline Expansion - ...